CINECA IRIS Institutional Research Information System

DURELLI, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.515
EU - Europa 7.328
AS - Asia 2.287
AF - Africa 177
Continente sconosciuto - Info sul continente non disponibili 40
SA - Sud America 32
OC - Oceania 31
Totale 17.410
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.383
IT - Italia 1.319
DE - Germania 1.294
CN - Cina 1.120
IE - Irlanda 839
UA - Ucraina 775
SE - Svezia 736
FR - Francia 578
FI - Finlandia 545
KR - Corea 499
GB - Regno Unito 400
SG - Singapore 293
PL - Polonia 243
AT - Austria 176
VN - Vietnam 151
SN - Senegal 134
CA - Canada 115
DK - Danimarca 110
IN - India 95
RU - Federazione Russa 94
NL - Olanda 41
GR - Grecia 39
EU - Europa 37
BE - Belgio 33
JP - Giappone 26
MU - Mauritius 26
ES - Italia 21
IR - Iran 21
AU - Australia 20
TR - Turchia 19
MX - Messico 16
BR - Brasile 15
NO - Norvegia 12
UZ - Uzbekistan 12
CZ - Repubblica Ceca 11
HK - Hong Kong 11
NZ - Nuova Zelanda 11
CH - Svizzera 10
RO - Romania 10
PT - Portogallo 8
IL - Israele 7
CO - Colombia 6
HU - Ungheria 6
ID - Indonesia 6
AL - Albania 5
BH - Bahrain 5
HR - Croazia 5
ZA - Sudafrica 5
BG - Bulgaria 4
MY - Malesia 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
EC - Ecuador 3
EE - Estonia 3
ET - Etiopia 3
SA - Arabia Saudita 3
TH - Thailandia 3
UY - Uruguay 3
AR - Argentina 2
CI - Costa d'Avorio 2
EG - Egitto 2
NG - Nigeria 2
OM - Oman 2
PE - Perù 2
TW - Taiwan 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
BD - Bangladesh 1
BY - Bielorussia 1
CL - Cile 1
CU - Cuba 1
DZ - Algeria 1
LB - Libano 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
NP - Nepal 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SI - Slovenia 1
ZW - Zimbabwe 1
Totale 17.410
Salva come PNG Salva come JPEG
Città #
Chandler 1.111
Beijing 847
Dublin 833
Ann Arbor 541
Jacksonville 432
Houston 408
Medford 345
Villeurbanne 321
Princeton 306
Ashburn 284
Fremont 257
Dearborn 246
Warsaw 241
Fairfield 231
Wilmington 225
Nyköping 223
Torino 197
Milan 196
Vienna 176
Singapore 156
Woodbridge 137
Boston 117
Dong Ket 106
Verona 86
Boardman 76
Rome 72
Seattle 61
Cambridge 58
Redwood City 56
Turin 51
Falls Church 50
Pisa 49
Norwalk 47
Guangzhou 43
Toronto 43
Lachine 40
New York 34
Nürnberg 34
Hefei 27
Nanjing 27
Brussels 23
Washington 21
San Diego 20
Los Angeles 19
Seongnam 19
Jinan 18
Menlo Park 17
Redmond 17
San Mateo 17
Kunming 16
London 16
Southampton 16
Pune 15
Dallas 14
Düsseldorf 14
Mountain View 14
Hangzhou 13
Leawood 13
Nanchang 13
Palermo 13
Shanghai 12
Duncan 11
Padova 11
Philadelphia 11
Seoul 11
Berlin 10
Catania 10
Paris 10
Amsterdam 9
Athens 9
Lappeenranta 9
Naples 9
Auburn Hills 8
Central District 8
Etroubles 8
Hebei 8
Helsinki 8
Madrid 8
Ottawa 8
Pavia 8
Phoenix 8
Stavanger 8
Wayne 8
Chicago 7
Kharkiv 7
Munich 7
Tokyo 7
Bologna 6
Brno 6
Castellammare di Stabia 6
Charlottesville 6
Chengdu 6
Des Moines 6
Durham 6
Florence 6
Frankfurt am Main 6
Hanoi 6
Leiden 6
Melbourne 6
Montecorvino Rovella 6
Totale 9.434
Salva come PNG Salva come JPEG
Nome #
Il Bergamini di Neurologia 657
Randomized trial of thymectomy in myasthenia gravis 419
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 375
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial 334
Computer assisted interactive learning in medical education: flipped classrooms of clinical neurology for medicine students 315
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 306
Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian independent registry 179
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 177
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 166
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 146
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 143
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study 141
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 135
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 132
Natalizumab in Multiple Sclerosis: Long-Term Management 129
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 122
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. 118
La riduzione della dose di ifn beta: “the switch dose study” 112
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 111
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 109
Treatment response to interferon beta: Biological (MxA protein or IL-10 mRNA level) or MRI indicators? 106
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab 103
The Real Life Impact of Early Versus delayed Treatment of Interferon beta on Long Term Disability Progression i relapsing-Remitting Multiple Sclerosis 101
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. 101
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP 101
A comparison of fully automatic and semi-manual contouring software for quantitative magnetic resonance imaging of lesion load in multiple sclerosis 100
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a 98
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis 93
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course 93
The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders 88
T HELPER 22 CELLS INCREASE IN MULTIPLE SCELROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 88
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 88
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b 87
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. 86
Follow-up of psychological features in patients treated with botulinum toxin type A 86
Impact on mental symptoms of botulinum toxin type A therapy in patients affected by focal dystonia and spasticity: preliminary results 83
TYPE 1 INTERFERON RECEPTOR (IFNA-R1). EXPRESSING TH17 LYMPHOCYTES ARE INCREASED DURING MS RELAPSES AND ARE SELECTIVELY INTHBITED BY IFNβ 83
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 83
Epigenetic therapy for Friedreich ataxia. 82
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 82
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation 81
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 81
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients 81
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b 80
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity 80
Cytokine and Chemokine mRNA in Peripheral Blood of MS Patients Correlates with Treatment response and Interferon Beta Dose 79
Comparison of immunomodulatory treatments for multiple sclerosis. 78
A case of canomad (chronic ataxic neuropathy, ophthalmoplegia, igm paraprotein, cold agglutinins and disialosyl antibodies) with transient cognitive impairment. 77
Estrogen Receptor Alpha- Associated Genomic Regions Are Potential Core of T Cell Subtypes Identity 77
Immunoglobulin treatment of multiple sclerosis: future prospects. 76
Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy. 76
T HELPER 22 CELLS INCREASE IN MULTIPLE SCLEROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 76
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 76
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 76
Anti-Gm1 And Anti-Sulfatide Antibodies In Polyneuropathies. Threshold Titers And Accuracy 75
Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial. 75
Estrogen receptor-alpha regulates epigenetic changes on genomic regulatory regions: potential biomarkers in multiple sclerosis outcomes 75
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). 74
Cytokines and Chemokine mRNA in perpheral blood of multiple sclerosis patients correlates with treatment response and interferon beta dose 74
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity. 74
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. 73
T helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β 73
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 73
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome 72
Th17, an effector T Lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon beta 72
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity 72
Psychological evaluation of quality of life in seizure-free epileptic patients 72
La dose ottimale di interferone beta: studio preliminare sulla tolleranza della dose di 375 microgrammi di interferone beta-1b 71
Treatment response indicators in multiple sclerosis. Persistence of mri activity during first months of immune-modulating drug treatment is predictive of persistence of clinical disease activity over the long term 70
IL 6, IL 10 IL 12, TNF-alpha anf IFN-gamma serum levels in secondary progressive multiple sclerosis patients treated with ifn-beta 1b and azathioprine or placebo: a two-year prospective study 70
T-helper 17 lymphocytes during MS relapses: antigen specificity and cytokine production. A multicentre longitunal study 70
Botulinum toxin A (Dysport) for treatment of sialorrhea in patients with neurologic disorders. 70
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 70
Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a. 69
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION) study: baseline data from a 2-years double blind, randomised, multicentre, pilot study. 69
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? 69
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 69
Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS. 68
Atypical presentation of superficial sclerosis successfully treated with iron chelation 68
Prophylaxis of chronic migraine with OnabotulinumtoxinA: experience and evidence in clinical practice 68
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study 68
A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes 67
To prevent conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane Metanalysis 67
ASPIRE ( Azathioprine Secondary Progressive Interferon treated patients Randomised Evaluation) study: 2-year double-blind and 1-year open, randomised, multicentre, pilot study. Multiple Sclerosis Functional Composite (MSFC) and magnetic resonance data 67
Clinically isolated syndrome: when to treat? A Cochrane analysis 67
Adherence to interferon-beta treatment and results of therapy switching 67
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 67
Is multiple sclerosis a disease that requires frequent beta interferon dosing? 66
Effects of taurine in chronic experimental epilepsy. 66
A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis 66
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a 66
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. 65
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION) study: baseline data from a 2-years double blind, randomized, multicentre, pilot study. 65
Assessing treatment response to immunomodulatory drugs for ms: a single active mri scan after 6 months of treatment is the best indicator of persisting disease activity 65
Peritoneal Dialysis and platelet infusion can be effective for MNGIE relapsing neuropathy not responding to intravenous high-dose gammaglobulin (IVIG) 65
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta 65
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 65
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 65
Th17 lymphocytes are expandend in multiple sclerosis and are inhibited by interferon beta 64
T-helper 17 lymphocytes increase during multiple sclerosis relapses and are inhibited by interferon beta 64
Totale 10.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.629
article - articoli 0
book - libri 0
conference - conferenze 30.663
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.292
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.595 84 143 261 353 227 353 271 133 274 239 151 106
2020/20212.180 284 98 229 156 165 107 136 75 372 151 173 234
2021/20222.466 57 55 86 144 100 137 155 135 87 255 459 796
2022/20233.424 427 232 71 368 270 947 284 217 315 75 156 62
2023/20241.337 147 215 65 101 88 184 29 49 4 85 92 278
2024/202536 36 0 0 0 0 0 0 0 0 0 0 0
Totale 18.210